These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38338712)

  • 21. Gene and drug matrix for personalized cancer therapy.
    Harris T
    Nat Rev Drug Discov; 2010 Aug; 9(8):660. PubMed ID: 20671766
    [No Abstract]   [Full Text] [Related]  

  • 22. Implementing a personalized medicine cancer program in a community cancer system.
    Dressler LG; Bell GC; Schuetze DP; Steciuk MR; Binns OA; Raab RE; Abernathy PM; Wilson CM; Kunutsor SE; Loveless MC; Ahearne PM; Messino MJ
    Per Med; 2019 May; 16(3):221-232. PubMed ID: 31109249
    [No Abstract]   [Full Text] [Related]  

  • 23. Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.
    Myklebost O
    Drug Discov Today; 2015 Dec; 20(12):1419-21. PubMed ID: 26520668
    [No Abstract]   [Full Text] [Related]  

  • 24. Deliberations about clinical pharmacogenetic testing in pediatric oncology.
    Issa AM; Aboushawareb SA; Eisenstat DD; Guilcher GM; Liu G; Rassekh SR; Strahlendorf C; Tallen G; Tanoshima R; Carleton B
    Per Med; 2021 Jul; 18(4):399-405. PubMed ID: 33973801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision medicine and the rapidly approaching future of cancer management.
    Markman M
    Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP207-8, cover. PubMed ID: 23301708
    [No Abstract]   [Full Text] [Related]  

  • 26. Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format.
    Diken M; Kreiter S; Kloke B; Sahin U
    Prog Tumor Res; 2015; 42():44-54. PubMed ID: 26383626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision.
    Sahakyan N; Haddad A; Richardson S; Forcha-Etieundem V; Christopher L; Alharbi H; Campbell R
    Anticancer Agents Med Chem; 2017; 17(8):1033-1039. PubMed ID: 28042778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tools in Pharmacogenomics Biomarker Identification for Cancer Patients.
    Scionti F; Di Martino MT; Caracciolo D; Pensabene L; Tagliaferri P; Arbitrio M
    Methods Mol Biol; 2022; 2401():1-12. PubMed ID: 34902118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Roles of Pharmacists in Cancer Genomic Medicine].
    Terada T
    Yakugaku Zasshi; 2020; 140(5):663-666. PubMed ID: 32378668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.
    Shinko D; Diakos CI; Clarke SJ; Charles KA
    Clin Pharmacol Ther; 2017 Oct; 102(4):599-610. PubMed ID: 28699186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine for cancer patients: worth a special issue.
    Höffken K
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):1. PubMed ID: 36637502
    [No Abstract]   [Full Text] [Related]  

  • 32. [The genome and cancer treatment].
    Nielsen FC; Lassen U
    Ugeskr Laeger; 2014 Nov; 176(46):. PubMed ID: 25394934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Precision Medicine for Personalized Cancer Therapy.
    Wong AH; Deng CX
    Int J Biol Sci; 2015; 11(12):1410-2. PubMed ID: 26681920
    [No Abstract]   [Full Text] [Related]  

  • 34. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.
    Hafez N; Walther Z; Eder JP; Sklar JL; Gettinger SN; Finberg KE; Goldberg SB
    Lancet Oncol; 2020 Mar; 21(3):343-344. PubMed ID: 32950226
    [No Abstract]   [Full Text] [Related]  

  • 36. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
    Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
    Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fusion Genes in Cancer-Toward Treatment from a Pan-Cancer Perspective].
    Nukaga S; Kohno T
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1030-1034. PubMed ID: 36281589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.
    Chau NG; Lorch JH
    Oncologist; 2015 Jul; 20(7):699-701. PubMed ID: 26040619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
    Tian Q; Price ND; Hood L
    J Intern Med; 2012 Feb; 271(2):111-21. PubMed ID: 22142401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer genomics: from discovery science to personalized medicine.
    Chin L; Andersen JN; Futreal PA
    Nat Med; 2011 Mar; 17(3):297-303. PubMed ID: 21383744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.